Cinctive Capital Management LP Acquires Shares of 56,801 Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Cinctive Capital Management LP acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 56,801 shares of the company's stock, valued at approximately $2,688,000. Cinctive Capital Management LP owned approximately 0.09% of Kymera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in shares of Kymera Therapeutics by 85.8% in the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock valued at $37,754,000 after acquiring an additional 368,394 shares during the period. FMR LLC increased its stake in Kymera Therapeutics by 5.8% in the third quarter. FMR LLC now owns 5,109,141 shares of the company's stock valued at $241,816,000 after purchasing an additional 282,301 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of Kymera Therapeutics in the second quarter valued at about $6,669,000. Renaissance Technologies LLC acquired a new stake in shares of Kymera Therapeutics during the second quarter worth about $4,271,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Kymera Therapeutics during the second quarter worth about $1,910,000.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.82% of the stock is owned by corporate insiders.

Kymera Therapeutics Trading Down 2.9 %

Shares of NASDAQ KYMR traded down $1.38 during trading on Tuesday, reaching $46.36. The company had a trading volume of 147,505 shares, compared to its average volume of 583,508. The stock has a market capitalization of $3.00 billion, a PE ratio of -20.40 and a beta of 2.16. Kymera Therapeutics, Inc. has a twelve month low of $20.32 and a twelve month high of $53.27. The stock has a 50-day moving average price of $46.82 and a two-hundred day moving average price of $42.26.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period in the previous year, the firm posted ($0.90) earnings per share. The company's quarterly revenue was down 20.9% compared to the same quarter last year. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

KYMR has been the topic of a number of analyst reports. Leerink Partners reiterated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Monday, September 9th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Morgan Stanley raised their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. Guggenheim lifted their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, November 1st. Finally, Truist Financial reissued a "buy" rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $53.40.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.